To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

Cancer and Leukemia Group B

From Wikipedia, the free encyclopedia

CALGB logo

Cancer and Leukemia Group B (CALGB; former name: Acute Leukemia Group B, ALGB) is a cancer research cooperative group in the United States.

CALGB research is focused on seven major disease areas: leukemia, lymphoma, breast cancer, lung cancer, gastrointestinal malignancies, genito-urinary malignancies, and melanoma. In each of these areas, multi-modality treatment programs are designed by national experts. CALGB is headquartered at the University of Chicago in Chicago, Illinois and maintains its statistical centers at Mayo Clinic in Rochester, Minnesota and Duke University in Durham, North Carolina.

YouTube Encyclopedic

  • 1/3
    Views:
    2 834 688
    5 760
    6 598
  • Why We Haven't Cured Cancer
  • An Answer to Cancer? Using the immune system to fight cancer -- Longwood Seminar
  • Leukemia and lymphoma

Transcription

According to the American Cancer Society, between one third and one half of the people in the United States will develop some form of cancer in their lifetimes. So scientists, doctors, and the many organizations that fund their research, are what you’d call “motivated” to find a cure. But... they haven’t found one, if you hadn’t heard. Plenty of drugs and treatments have been tested, but they often don’t seem to work. One person can take a cancer drug and get better, but another person -- with the same type of cancer -- can take the same drug and not get better. So, after billions of dollars and decades of research, why haven’t we cured cancer? Well, a better question is why do we keep talking about “THE cure for cancer"? If every tumor worked the same, we would probably by now have that magic bullet that we need. The trouble is, cancers may look the same on the outside, but each one develops differently in their own way, and can originate in any type of tissue. So we haven’t found a cure for cancer, because it’s not a single disease. If we’re going to beat them, we’re going to have to take on all of the cancers, one at a time. So the challenges start with the basics here: first we’ve got to figure out what cancer actually is. We tend to think of cancer as one thing because we have one word for it. But the word “cancer” really refers to lots of different conditions that have a few similarities. The main thing cancers have in common is uncontrolled cell division. And that uncontrolled growth usually starts from a sudden change within a small set of your genes. No matter what triggers it, you get the same result: a mass of cells growing out of control and invading other tissues, which is very bad for the body. But under the hood, each cancer works differently. It’s practically a different disease every time, and not every cancer will progress in the same order. Mostly, that’s because every cancer is caused by a different set of genetic mutations. Genes consist of a sequence of DNA, and each sequence is a set of chemical bases called nucleotides that are arranged in a very specific order. Together, they tell the cell how to manufacture proteins, and we are mostly just made up of proteins - so that’s how we build ourselves. Mutations change those instructions, and that’s where things start to go wrong. Now, we know by this point that cancers usually come from mutations of two kinds of genes, called oncogenes and tumor suppressors. An oncogene starts out as just a normal gene that codes for proteins that signal the cell to grow. And normally, they just spend a lot of their time dormant, because growth is generally good, but cells shouldn’t always be growing. But just one mutation in one of these genes is often enough to throw it into high gear, and it can’t be turned off. That’s when it becomes an oncogene, telling the cell to keep growing and dividing over and over, even when it shouldn’t. That’s also when it gets dangerous. Some of the most well-known oncogenes -- the usual suspects, if you will -- are RAS and MYC. They’re especially powerful growth genes that show up in many kinds of cancer. A lot of the time, it’s the RAS gene that somehow gets mutated, which changes the shape of the protein that it makes. The altered protein gets stuck in a position that always sends a signal for the cell to grow, whether it’s supposed to or not. And with its new shape, other proteins -- ones that usually deactivate the RAS protein before things can get out of hand -- can’t recognize what they’re supposed to be targeting and switch it off. So the cell never stops getting the signal to grow and divide, and it starts forming a tumor. Then there are tumor suppressors, another type of cancer-causing gene -- and they’re actually the opposite of oncogenes. As you might guess from their name, tumor suppressors stop a cell from growing, unless conditions are just right. As with all of your genes, every cell in your body has two copies of the tumor suppressor, so they’re harder to put out of commission: Even when one copy is mutated, the other one still works. But of course, cancer has a tendency to find its way around all kinds of safeguards. Often, a tumor suppressor might be mutated on one chromosome to the point of not working at all. Then, the cell just happens to lose the chunk of DNA containing the other copy. With one copy mutated and the other deleted, there’s no tumor suppressor left to restrain the cell’s growth. And those mutations can happen in any number of ways. With so many possible combinations, we can’t just create a drug to keep tumor suppressors from mutating. Which is where things start to get even more complicated. Because just one mutated gene isn’t usually enough to cause cancer -- it really takes at least five or six genetic changes before normal human cells become truly cancerous. Then, as tumors get bigger, more and more genes tend to mutate. Some of those mutations make the cancer nastier and more aggressive. How quickly this happens varies a lot, with different rates being associated with certain kinds of cancer. But there can be thousands of possible combinations of mutations going on in a cell -- which is partly why a drug might not work for some patients, even if it’s proven effective for that type of cancer. So every single tumor will follow a different genetic path, which makes it hard for doctors and drug-makers to know what to target. So how do you kill a tumor cell, when you don’t know which of the potentially dozens of problematic genes are making it grow? The most obvious way to treat a tumor is to get a knife and cut it out of the body. That’s called resecting it. But it’s not always possible, and even when it is, sometimes they grow back. So typically, you go to Plan B: Use a blunt instrument to smash the cancer, and hope for the best. For a long time, the best cancer therapy we’ve had is to send in a treatment so toxic it attacks all rapidly dividing cells in the human body, instead of just the cancer. Those treatments are chemotherapy and radiation. The kind of radiation that’s useful in cancer treatment is ionizing radiation -- the kind whose energy can ionize atoms, and the kind that most people mean when they talk about “radiation.” And it works simply because it can tear DNA to shreds. Once the cancer cell’s DNA is mangled beyond recognition, it can no longer make copies and divide. But of course, it damages the DNA of nearby, healthy cells too. So doctors try to aim it right at the tumor, to expose as little healthy tissue to the radiation as possible. And then there’s the group of drugs we refer to collectively as chemotherapy. These drugs work in a few different ways, but because they circulate through the bloodstream, they tend to affect the whole body. Some types of chemo imitate one of the building blocks of DNA, so that cells try to incorporate them into their chromosomes without realizing they’re useless. Other kinds target the cell’s cytoskeleton -- its internal framework -- so that it can’t pull itself apart when it divides. These kinds of chemo can stop a cancer cell from dividing -- but again, there are a lot of healthy cells in your body that need to divide, as well. Hair follicles need to go on producing hair, and the lining of your gut needs to constantly renew itself against harsh stomach acids. That’s why chemo causes hair loss and digestive symptoms, along with a whole bunch of other nasty side effects. It can work, but it isn’t pretty. Fortunately, there are new alternatives. One of the newest weapons in the battle against cancer is one that biologists have been refining for decades: Genome sequencing. It’s faster and cheaper than anyone dreamed possible even ten years ago, and it’s finally ready to directly help patients. Within a matter of days, scientists can now sequence lots of different types of cancer cells, and figure out exactly where and how their genes were mutated. Using that information, they can predict what drugs will be effective against those cancers. So, instead of using a blunt instrument that kills pretty much everything it touches, we can develop much more refined ways to treat a certain cancer, in a certain person, through personalized medicine. Two major projects have taken the lead on this new approach -- one’s called the Cancer Genome Project and the other, the Cancer Cell Line Encyclopedia. They’ve tested many kinds of cancer cells and drugs on a large scale. In both cases, researchers confirmed that certain drugs are more effective against particular types of cancer. Some drugs, for instance, work better for brain cancer than stomach cancer. They also found that they could predict the effectiveness of a drug based on the mutations that they find in a particular set of cancer cells. So choosing drugs for cancer treatment doesn’t have to be a shot in the dark anymore -- at least, in theory. There’s a serious problem, though. One study compared the results of the Cancer Genome Project and the Cancer Cell Line Encyclopedia, and it found that they came to different conclusions alarmingly often. When the two different groups of researchers treated the same cancer cells with the same drugs in a lab, they got different results. Even though the cells they used were more or less identical, they would sometimes respond differently to the exact same drugs. And even when the two projects agreed that a drug could treat a certain kind of cancer, they disagreed about what dose was needed to be effective. So, we won’t be able to count on personalized medicine to work until scientists come up with more effective ways to test these drugs, and figure out how to use them in people. So there are still some glitches to work out, but it’s probably the most promising lead we have in the fight against cancer. So it’s true: We haven’t found one cure for cancer yet, but that’s kind of a question wrongly asked; there is no cancer to cure -- there are lots of cancers we need to cure. Advances in things like DNA sequencing mean that, even though there are as many cancers as there are cancer patients, soon there may be as many cancer treatments as there are cancers. And that’s pretty good news. Thank you for watching this scishow infusion; I hope it was educational for you. It was made possible by our patrons on Patreon. If you want to help us keep making videos like this, check out patreon.com/scishow. And don’t forget to go to youtube.com/scishow and subscribe for more.

History

The group that was to become known as the CALGB got its roots when James F. Holland initiated a clinical trial for acute leukemia in 1953 while at the National Cancer Institute. In 1954, before the trial was complete, Holland moved to Roswell Park Comprehensive Cancer Center (then known as Roswell Park Memorial Institute), but the new chief of oncology Gordon Zubrod at the NCI agreed to continue the trial, and a multicenter trial was thus born. In 1955, Congress granted $5 million for the study of chemotherapy and began the Chemotherapy National Service Center which was headquartered at the NCI. An interinstitutional protocol for the treatment of leukemia was started by Emil "Tom" Frei at the NCI, involving three groups: NCI, RPMI, and Children's Hospital in Buffalo.

In 1956, this group was designated the Acute Leukemia Group B by the Chemotherapy National Service Center, and Frei became its chairman. (There was also an Acute Leukemia Group A, which later became the Children's Cancer Study Group.[1]) During this time, the group expanded to a national level. Holland became the new chairman in 1962 after Frei resigned. The group changed its name to Cancer and Leukemia Group B in 1976 to reflect its role with solid tumors as well as leukemia.

In March 2011, CALGB merged with two other cooperative groups, the American College of Surgeons Oncology Group (ACOSOG) and North Central Cancer Treatment Group (NCCTG), to form the Alliance for Clinical Trials in Oncology. This was due to the call in April 2010 from the Institute of Medicine to strengthen and streamline operations among NCI clinical trials cooperative group programs.[2] In June 2010, ACOSOG, CALGB and NCCTG integrated their statistical, data management and information technology functions. Having already merged some functions, the three groups began evaluating the possibility of full integration to further streamline operations, expand their scientific research opportunities, and apply for funding as a new, larger cooperative group.

In June 2011, governing boards of ACOSOG, CALGB and NCCTG endorsed a proposed Alliance constitution, bylaws and transition plan. The Transition Alliance Board of Directors then ratified the constitution and elected a new Group Chair, Monica M. Bertagnolli, MD, along with board members to serve on the Executive Committee. The first Alliance Group Meeting was held in November 2011 in Chicago, Illinois. The merger was completed in 2014.[3]

Function

CALGB Research Objectives

  • To answer important therapeutic questions through large clinical trials
  • To develop a strong multidisciplinary approach to cancer treatment and prevention
  • To integrate information obtained from basic science and from economic and psychosocial investigations with information from clinical trials
  • To explore the relationship between dose density and therapeutic outcome
  • To systematically explore methods of optimizing treatment for individual patients
  • To introduce novel therapies and treatment approaches for patients with poor prognoses
  • To study quality of life and impact of cost on cancer patients
  • To encourage fresh and innovative ideas of new investigators
  • To involve community hospitals in CALGB cancer research
  • To maintain a high degree of quality control in all CALGB science
  • To increase participation of minority populations, the elderly and women in clinical trials
  • To collect, analyze, and publish the results of CALGB studies

Studies

The number of CALGB protocols involving multimodality treatment of adult solid tumors has increased steadily over the years. Areas of particular interest within CALGB are the role of minimally invasive surgery in patients receiving state-of-the-art multimodality therapy as well as neoadjuvant therapy prior to surgery.

During the 1970s, the CALGB initiated the application of immunologic methods for the study of leukemia and lymphoma. Continuing with progressively more sophisticated studies, interest has expanded to include the application of molecular-genetic techniques to characterize leukemias, lymphomas, and solid tumors at the gene level.

Pharmacokinetic data are important for determining the optimal dose or schedule of a drug. The Pharmacology & Experimental Therapeutics Committee has increasingly focused on pharmacogenetics, the study of how genetic variation may impact on the toxicity or efficacy of drug therapy. The CALGB has a long history of accomplishments in evaluating new therapeutic agents. The Group has developed innovative strategies for testing new agents while allowing patients to receive standard therapies.

The CALGB has pioneered the use of telephone interviews for data collection concerning quality of life in cancer patients. Studies exploring the relationship between therapy and quality of life and the economic impact of new treatments are underway. CALGB has been among the leaders in designing studies specifically assess the pharmacology and tolerance of chemotherapy in older patients, barriers to treatment of older patients on clinical trials, and therapeutic options for older women with early stage breast cancer.

Study development and monitoring

The concept for a new study originated by a CALGB member is discussed by the Disease Committee and Modality Committee core; it is then discussed by the full committee. The committee chairs bring the concept to the Executive Committee and, if approved, the Study Chair develops a draft protocol. The relevant Committee Chair, the responsible Statistician, appropriate chairs of other Disease and Modality committees, patient advocates, and the Principal Investigators at the main member institutions are involved in the protocol design. After CALGB review and NCI approval, the Central Office officially activates the protocol. A Data and Safety Monitoring Board (DSMB) periodically reviews interim reports prepared by the Statistical Center for all Phase III studies. When the required number of patients has been entered on a study, the study is closed. The DSMB may elect to terminate a protocol early or to continue a study beyond its intended accrual. Final analysis of the data is the responsibility of the Statistical Center and the Study Chair.

The CALGB Radiation Oncology Quality Assurance Subcommittee reviews CALGB data under the auspices of the Quality Assurance Review Center (QARC) in Lincoln, Rhode Island. QARC was organized to monitor radiotherapy quality assurance programs for several cooperative groups and is supported independently of the CALGB. Today QARC provides radiotherapy quality assurance and diagnostic imaging data management to all of the National Cancer Institute (NCI) sponsored cooperative groups. These groups include CALGB, the Children's Oncology Group (COG), the Eastern Cooperative Oncology Group (ECOG), the Southwest Oncology Group (SWOG), and others. Although QARC is largely supported by grants from the NCI and NIH (National Institutes of Health), the center also contracts privately with the pharmaceutical industry so as to offer its services in clinical trials for anti-cancer drugs. Lastly, QARC maintains a strategic affiliation with the University of Massachusetts Medical School (UMMS) in Worcester, Massachusetts.

The Institutional Performance Evaluation Committee (IPEC) develops and implements standards of performance for the CALGB and reviews performance of protocol requirements and quality of data submitted by individual institutions on a semi-annual basis.

The CALGB protects the privacy of our clinical trial participants as required by law. The CALGB recognizes the importance of policies and procedures that encourage women and minority participation in CALGB clinical trials; currently, more than 50% of CALGB study patients are women. The Minority Initiative program was created to increase the number of minority patients participating in CALGB studies. Particular attention is directed toward developing protocols that focus on diseases that exact a heavy toll on minority populations.

References

  1. ^ Holland, James F. (Summer 1996). "Reflections on 40 Years of the CALGB" (PDF). The CALGB Newsletter. Vol. 5, no. 2. pp. 15–18.
  2. ^ Reinvigorating the NCI cooperative Archived 2013-08-25 at the Wayback Machine>
  3. ^ Alliance for Clinical Trials in Oncology: History

External links

This page was last edited on 4 June 2022, at 16:05
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.